News | September 09, 2025
SPL Infusion commences commercial production of new IV fluid Infusion plant
The facility has been designed with a dual focus on efficiency and sustainability
The facility has been designed with a dual focus on efficiency and sustainability
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Lupin will address the observations and respond to the U.S. FDA within the stipulated timeframe
PendraCare Group develops, manufactures and sells innovative cardiology catheter solutions and provides design, development and manufacturing services to other global OEM’s
Zydus will work closely with the USFDA to address and resolve the observations in an expeditious manner
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
The U.S. FDA issued a Form 483 with five observations
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Subscribe To Our Newsletter & Stay Updated
